Factors Associated with PFS and OS (with Univariate Analysis)
| PFS | OS | |||
| Factor | Months | P | Months | P |
| TD (< vs. ≥ 205 Gy) | 3.5 (2–5) vs. 10 (7–11) | 0.0029 | 4.3 (3.7–5) vs. 18.2 (8.5–28.7) | 0.005 |
| PVT targeting (good vs. poor) | NA* | 3 (3–5) vs. 20.9 (12–27) | <0.0001 | |
| Good vs. poor candidate† | 5 (2–5) vs. 10 (7–11) | <0.0001 | 3 (3–3.7) vs. 20.2 (12–25.1) | <0.0001 |
| Main PVT vs. lobar or segmental | 5.5 (3–13) vs. 10 (6–11) | NS | 11.5 (11–25.2) vs. 21.5 (11–28.5) | NS |
| Child A and lobar PVT vs. others | 10 (7–16) vs. 8 (4–10) | NS | 13.75 (3–27) vs. 23.2 (8–23.7) | NS |
| Child–Pugh (A5 vs. A6 + B7) | 6 (3.5–11) vs. 10 (7–15.2) | NS | 23.7 (12–36.7) vs. 7 (3–21.5) | 0.015 |
| Type (U vs. M and D) | 10 (6–11) vs. 8 (2–15.2) | NS | 11.5 (3.7–23) vs. 25.2 (12–36.7) | NS |
| Unilateral vs. bilateral disease | 10 (7–13) vs. 6 (2–11) | NS | 17.85 ( 9–25.2) vs. bilateral 18 (0–∞) | NS |
| Tumoral involvement < or ≥ 50% | 8 (2–15.2) vs. 10 (6–11) | NS | 17.5 (11–25.2) vs. 38 (3–38) | NS |
| size (≤5 vs. >5 cm) | 7 (3–∞) vs. 9 (6–11) | NS | 30 (2.2–∞) vs. 17 (11–25.2) | NS |
| CLIP (stage 0–2 vs. 3 and 4) | 9 (2–10) vs. 10 (5–15.2) | NS | 21.5 (8.5–28.7) vs. 15.5 (3–27) | NS |
| α-fetoprotein level (≤400 vs. >400) | 11 (5–16.5) vs. 8.5 (5–10) | 0.02 | 21.5 (11–36.7) vs. 14.5 (3–25.2) | NS |
| Bilirubin level (≤36 vs. >36 μmol/L) | 9 (6–11) vs. 5 (3.5–∞) | NS | 18.2 (12–27) vs. 3.2 (0–36.7) | NS |
| ECOG status (0 vs. 1 or 2) | 10 (8–15) vs. 5 (2.10) | 0.02 | 18.2 (12–27) vs. 11 (3–∞) | NS |
| Treatment line (first vs. others) | 8.5 (5–11) vs. 10 (5–16.5) | NS | 24.5 (3–36.7) vs. 14.5 (8.5–25.2) | NS |
| Surgery (yes vs. no) | 10 (8–16) vs. 8.5 (6–11) | NS | 15.0 (8.5–21.5) vs. not reached (24.5–∞) | 0.0493 |
↵* Patients with no PVT targeting died before progression.
↵† A good candidate is defined as patient with both TD ≥ 205 Gy and good PVT targeting. A poor candidate is defined as exhibiting TD < 205 Gy or poor PVT targeting or both.
NA = not applicable; NS = not statistically significant; U = unifocal; M = multifocal; D = diffuse; CLIP = cancer of liver Italian program; ECOG = Eastern Cooperative Oncology Group.
Data are median followed by 95% confidence interval in parentheses.